II. Physiology
- See Estradiol
 
III. Symptoms: Excess Estrogen (e.g. Premenstrual Syndrome)
IV. Pharmacokinetics: Relative Potency
- Ethinyl Estradiol: 100
 - Mestranol: 67
 
V. Precautions
- Mestranol is potentially a carcinogen (animal studies)
 - MI, CVA, DVT, PE and Breast Cancer risk are all FDA Black box warnings
 
VI. Preparations: Hormone Replacement Dosages (unless otherwise noted)
- Micronized Estradiol (Estrace)
- Take 1 to 2 mg orally daily
 
 - Ethinyl Estradiol
- Oral Contraceptive: 0.03 to 0.10 mg/day (primary use)
 - Hormone Replacement: 0.005 to 0.02 mg/day
- Other Estrogen formulations are typically used for Hormone Replacement
 
 
 - 
                          Estradiol Cypionate (Depo-Estradiol)
- Inject 1 to 5 mg IM every 3-4 weeks
 
 - 
                          Estradiol valerate (Delestrogen)
- Inject 2-20 mg IM every other week
 - Also found in some Oral Contraceptives
 
 - Estropipate (1.25-2.5 mg/day)
 - Conjugated Estrogen (e.g. Premarin, Enjuvia)
- Oral (0.3-1.25 mg/day)
 - Injectable (0.2-2 mg/day)
 - Transdermal
 
 - Diethylstilbestrol (0.1-0.5 mg/day)
 - Quinestrol (0.1-0.2 mg/week)
 - Chlorotrianisene (12-25 mg/day)
 - Methallenestril (3-9 mg/day)
 - Esterified Estrogen (Menest): 0.3 to 1.25 mg/day
 
VII. Preparations: Native Estrogen with Selective Actions in Tissues (NEST)
- Background
- Native Estrogen with Selective Actions in Tissues (NEST) are plant-derived Estrogens (Phytoestrogens)
 - Low potency and therefore 1000-fold higher doses are required (measured in mg NOT mcg)
- Nextstellis contains 14.2 mg of Estetrol, while most OCPs contain 20-30 mcg Ethinyl Estradiol
 
 
 - Estetrol (E4)
- Estetrol is a new plant-derived Estrogen (E4) formulation available in 2021 as component of Nextstellis OCP
 - Carries same Estrogen-related effects and contraindications
 
 - References
- (2021) Presc Lett 28(7): 38